ArticleGut and liver2017

Simeprevir-Based Triple Therapy with Reduced Doses of Pegylated Interferon α-2a Plus Ribavirin for Interferon Ineligible Patients with Genotype 1b Hepatitis C Virus.

Hideyuki Tamai et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.